Literature DB >> 16123953

Hemodynamics and survival of patients with portopulmonary hypertension.

Steven M Kawut1, Darren B Taichman, Vivek N Ahya, Sandra Kaplan, Christine L Archer-Chicko, Stephen E Kimmel, Harold I Palevsky.   

Abstract

It is not known whether patients with pulmonary arterial hypertension associated with portal hypertension (portopulmonary hypertension (PPHTN) have different disease characteristics from those of patients with other forms of pulmonary arterial hypertension. We performed a retrospective cohort study of patients with PPHTN and patients with pulmonary arterial hypertension that was idiopathic, familial, or associated with anorexigen use (IPAH) to determine whether hemodynamics or survival were different between these groups. We included consecutive patients who underwent initial pulmonary artery catheterization and vasodilator testing at our center between January 1997 and May 2001 and who were followed until January 2004. Patients with PPHTN (N = 13) had a higher cardiac index and lower pulmonary vascular resistance than patients with IPAH (N = 33) (P < or = 0.001). Right atrial pressure and pulmonary artery pressure were similar between the groups. Patients with PPHTN had a higher risk of death in multivariate analysis (hazard ratio: [HR] = 2.8, 95% CI 1.04-7.4; P = 0.04). These findings were not affected by adjustment for differences in laboratory values, hemodynamics, or therapy. In conclusion, patients with PPHTN have a higher risk of death than that of patients with IPAH, despite having a higher cardiac index and lower pulmonary vascular resistance. Future studies of the specific mechanisms of and therapy for pulmonary arterial hypertension should focus on the distinctions between the different forms of this disease.

Entities:  

Mesh:

Year:  2005        PMID: 16123953     DOI: 10.1002/lt.20459

Source DB:  PubMed          Journal:  Liver Transpl        ISSN: 1527-6465            Impact factor:   5.799


  37 in total

1.  Pulmonary complications of cirrhosis.

Authors:  Rajan Kochar; Moises I Nevah Rubin; Michael B Fallon
Journal:  Curr Gastroenterol Rep       Date:  2011-02

2.  Recommendations for the assessment and reporting of multivariable logistic regression in transplantation literature.

Authors:  A C Kalil; J Mattei; D F Florescu; J Sun; R S Kalil
Journal:  Am J Transplant       Date:  2010-07       Impact factor: 8.086

3.  Portopulmonary hypertension: challenges in diagnosis and management.

Authors:  Patrick J Troy; Aaron B Waxman
Journal:  Therap Adv Gastroenterol       Date:  2009-09       Impact factor: 4.409

Review 4.  Portopulmonary hypertension.

Authors:  Michael Halank; Ralf Ewert; Hans-Juergen Seyfarth; Gert Hoeffken
Journal:  J Gastroenterol       Date:  2006-09       Impact factor: 7.527

5.  Portopulmonary hypertension.

Authors:  Ravi P Nayak; Dechun Li; George M Matuschak
Journal:  Curr Gastroenterol Rep       Date:  2009-02

6.  Effectiveness of phosphodiesterase-5 inhibitor therapy for portopulmonary hypertension.

Authors:  Jolene H Fisher; Sindhu R Johnson; Cathy Chau; Amie T Kron; John T Granton
Journal:  Can Respir J       Date:  2014-12-18       Impact factor: 2.409

7.  Hemodynamic predictors of mortality in adults with sickle cell disease.

Authors:  Alem Mehari; Shoaib Alam; Xin Tian; Michael J Cuttica; Christopher F Barnett; George Miles; Dihua Xu; Catherine Seamon; Patricia Adams-Graves; Oswaldo L Castro; Caterina P Minniti; Vandana Sachdev; James G Taylor; Gregory J Kato; Roberto F Machado
Journal:  Am J Respir Crit Care Med       Date:  2013-04-15       Impact factor: 21.405

8.  Serotonin transporter polymorphisms in patients with portopulmonary hypertension.

Authors:  Kari E Roberts; Michael B Fallon; Michael J Krowka; Raymond L Benza; James A Knowles; David B Badesch; Robert S Brown; Darren B Taichman; James Trotter; Steven Zacks; Evelyn M Horn; Steven M Kawut
Journal:  Chest       Date:  2009-01-13       Impact factor: 9.410

9.  Genetic risk factors for portopulmonary hypertension in patients with advanced liver disease.

Authors:  Kari E Roberts; Michael B Fallon; Michael J Krowka; Robert S Brown; James F Trotter; Inga Peter; Hocine Tighiouart; James A Knowles; Daniel Rabinowitz; Raymond L Benza; David B Badesch; Darren B Taichman; Evelyn M Horn; Steven Zacks; Neil Kaplowitz; Steven M Kawut
Journal:  Am J Respir Crit Care Med       Date:  2009-02-12       Impact factor: 21.405

Review 10.  Pulmonary vascular complications of liver disease.

Authors:  Jason S Fritz; Michael B Fallon; Steven M Kawut
Journal:  Am J Respir Crit Care Med       Date:  2012-11-15       Impact factor: 21.405

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.